SACGT Induces Test Maker Sponsorship Of Follow-Up Trials, Taps Myriad
This article was originally published in The Gray Sheet
The HHS Secretary's Advisory Committee on Genetic Testing plans to charge its data work group with investigating the department's role in providing incentives for manufacturers to continue follow-up studies where data is lacking on clinical utility and validity for commercialized tests
You may also be interested in...
Myriad Genetics assumes Oncormed's BRCA1/BRCA2 breast and ovarian genetic testing business and exclusive rights to Oncormed's current and pending patents for BRCA1/BRCA2 under terms of a patent infringement settlement jointly announced May 18. Oncormed will transfer to Myriad, for undisclosed fees, the components of its genetic testing business, including professional contacts and customer lists. Each company retains diagnostic and therapeutic rights in their respective patents. Oncormed initiated the suit in November, alleging that Myriad's BRACAnalysis genetic testing service infringed its BRCA1-related patent. Myriad then filed its own suit in December, claiming that Oncormed infringed a Myriad patent related to breast and ovarian cancer susceptibility genes ("The Gray Sheet" Dec. 8, 1997, In Brief)
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.